Finance

Lists
Why is LSTA down 4,59%?
Dive Deeper
LSTA:NASDAQ
Lisata Therapeutics, Inc.
1,04 $
-4,59%
(-0,050) 1D
17 նոյ, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LSTA...
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
246,91 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
246,91 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com
Analyst
Recommendation
Action
Price target
Projected
Date
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
07/27/2026
Joseph Pantginis
H.C. Wainwright
Hold
Downgraded
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
100,00 հզր
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1,13 մլն
1,20 մլն
584,00 հզր
5,21 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,04 մլն
3,74 մլն
3,41 մլն
4,82 մլն
Operating expense
3,18 մլն
4,94 մլն
3,99 մլն
10,03 մլն
Total operating expenses
3,18 մլն
4,94 մլն
3,99 մլն
10,03 մլն
Operating income
-3,08 մլն
-4,94 մլն
-3,99 մլն
-10,03 մլն
Other non operating income
-16,00 հզր
-16,00 հզր
984,00 հզր
-3,06 մլն
EBT including unusual items
-2,95 մլն
-4,88 մլն
-2,93 մլն
-12,81 մլն
EBT excluding unusual items
-2,95 մլն
-4,84 մլն
-2,93 մլն
-12,81 մլն
Income tax expense
-
-387,00 հզր
-
-6,03 մլն
Effective tax rate
-
7,94%
-
47,03%
Other operating expenses
-
-
-
-
Net income
-2,95 մլն
-4,49 մլն
-2,93 մլն
-6,79 մլն
Net profit margin
-2 954,00%
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
141,00 հզր
120,00 հզր
79,00 հզր
273,00 հզր
Interest expense
-
-
-
-
Net interest expenses
141,00 հզր
120,00 հզր
79,00 հզր
273,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-3,06 մլն
-4,94 մլն
-3,99 մլն
-10,03 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps